The Trump administration has abruptly halted the USAid Malaria Vaccine Development Program (MVDP), which aimed to create better malaria vaccines, effectively disrupting ongoing health research worldwide. This funding freeze affects critical efforts to reduce malaria-related child mortality, particularly in sub-Saharan Africa, where malaria claims approximately 450,000 lives among children under five each year. Experts warn that this sudden stop may lead to increased drug-resistant HIV and setbacks in medical innovation, particularly concerning the testing and safety of new vaccines currently under research. The review process initiated by the freeze remains uncertain due to a lack of expertise in senior health positions.
The sudden halt of the USAid Malaria Vaccine Development Program by the Trump administration reflects a broader disruption to health research worldwide that poses risks to progress.
Researchers warn the freeze could fuel the spread of drug-resistant HIV and significantly delay medical advancements by years.
The abrupt stop of ongoing trials raises huge safety implications, particularly as many projects are testing new vaccines in humans for the first time.
Sources in health research express uncertainty about who will conduct the necessary reviews amid significant turnover among senior officials at US health bodies.
Collection
[
|
...
]